Anticancer drugs repurposed for Alzheimer's disease: a systematic review.
Alzheimer’s disease
Anticancer drugs
Cancer
Clinical trials
Drug repositioning
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
05 05 2021
05 05 2021
Historique:
received:
10
02
2021
accepted:
19
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
25
6
2021
Statut:
epublish
Résumé
The relationship between cancer and dementia is triggering growing research interest. Several preclinical studies have provided the biological rationale for the repurposing of specific anticancer agents in Alzheimer's disease (AD), and a growing number of research protocols are testing their efficacy and safety/tolerability in patients with AD. The aim of the present systematic review was to provide an overview on the repurposing of approved anticancer drugs in clinical trials for AD by considering both ongoing and completed research protocols in all phases. In parallel, a systematic literature review was conducted on PubMed, ISI Web, and the Cochrane Library to identify published clinical studies on repurposed anticancer agents in AD. Based on a structured search on the ClinicalTrials.gov and the EudraCT databases, we identified 13 clinical trials testing 11 different approved anticancer agents (five tyrosine kinase inhibitors, two retinoid X receptor agonists, two immunomodulatory agents, one histone deacetylase inhibitor, and one monoclonal antibody) in the AD continuum. The systematic literature search led to the identification of five published studies (one phase I, three phase II, and one phase IIb/III) reporting the effects of antitumoral treatments in patients with mild cognitive impairment or AD dementia. The clinical findings and the methodological characteristics of these studies are described and discussed. Anticancer agents are triggering growing interest in the context of repurposed therapies in AD. Several clinical trials are underway, and data are expected to be available in the near future. To date, data emerging from published clinical studies are controversial. The promising results emerging from preclinical studies and identified research protocols should be confirmed and extended by larger, adequately designed, and high-quality clinical trials.
Sections du résumé
BACKGROUND
The relationship between cancer and dementia is triggering growing research interest. Several preclinical studies have provided the biological rationale for the repurposing of specific anticancer agents in Alzheimer's disease (AD), and a growing number of research protocols are testing their efficacy and safety/tolerability in patients with AD.
METHODS
The aim of the present systematic review was to provide an overview on the repurposing of approved anticancer drugs in clinical trials for AD by considering both ongoing and completed research protocols in all phases. In parallel, a systematic literature review was conducted on PubMed, ISI Web, and the Cochrane Library to identify published clinical studies on repurposed anticancer agents in AD.
RESULTS
Based on a structured search on the ClinicalTrials.gov and the EudraCT databases, we identified 13 clinical trials testing 11 different approved anticancer agents (five tyrosine kinase inhibitors, two retinoid X receptor agonists, two immunomodulatory agents, one histone deacetylase inhibitor, and one monoclonal antibody) in the AD continuum. The systematic literature search led to the identification of five published studies (one phase I, three phase II, and one phase IIb/III) reporting the effects of antitumoral treatments in patients with mild cognitive impairment or AD dementia. The clinical findings and the methodological characteristics of these studies are described and discussed.
CONCLUSION
Anticancer agents are triggering growing interest in the context of repurposed therapies in AD. Several clinical trials are underway, and data are expected to be available in the near future. To date, data emerging from published clinical studies are controversial. The promising results emerging from preclinical studies and identified research protocols should be confirmed and extended by larger, adequately designed, and high-quality clinical trials.
Identifiants
pubmed: 33952306
doi: 10.1186/s13195-021-00831-6
pii: 10.1186/s13195-021-00831-6
pmc: PMC8101105
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
96Références
J Biomed Sci. 2020 Jan 6;27(1):18
pubmed: 31906949
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Ther Adv Hematol. 2018 Jul;9(7):175-190
pubmed: 30013765
J Neuroinflammation. 2018 Nov 9;15(1):311
pubmed: 30413160
Alzheimers Dement. 2017 Dec;13(12):1364-1370
pubmed: 28711346
Cancer Chemother Pharmacol. 2010 Jan;65(2):201-5
pubmed: 19777233
J Neurosci. 2008 Aug 13;28(33):8354-60
pubmed: 18701698
J Alzheimers Dis. 2020;76(4):1339-1345
pubmed: 32623401
Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S1-6
pubmed: 9769023
Cells. 2020 Feb 18;9(2):
pubmed: 32085567
Neuroscience. 2015 Sep 24;304:316-27
pubmed: 26235435
Front Cell Neurosci. 2014 Aug 12;8:233
pubmed: 25161610
Drugs R D. 2019 Jun;19(2):149-166
pubmed: 30919310
J Alzheimers Dis. 2016 Oct 4;54(3):853-857
pubmed: 27716676
Biol Pharm Bull. 2012;35(8):1206-12
pubmed: 22863914
Oncogene. 2011 Feb 17;30(7):757-69
pubmed: 21057534
Sci Adv. 2016 Feb 12;2(2):e1501244
pubmed: 26933687
Dement Geriatr Cogn Disord. 2013;35(1-2):1-22
pubmed: 23307039
Expert Rev Neurother. 2015 Jun;15(6):587-96
pubmed: 25961655
Drugs. 2017 Jan;77(1):85-96
pubmed: 28032244
Neurochem Int. 2020 Nov;140:104841
pubmed: 32853752
J Neuroinflammation. 2018 Feb 15;15(1):43
pubmed: 29448961
Cells. 2020 Jul 30;9(8):
pubmed: 32751526
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Neurobiol Dis. 2008 Feb;29(2):254-66
pubmed: 17964176
Am J Clin Oncol. 2010 Dec;33(6):533-43
pubmed: 20023570
Alzheimers Dement (N Y). 2016 Jun 17;2(2):110-120
pubmed: 29067298
Alzheimers Res Ther. 2020 Aug 17;12(1):98
pubmed: 32807237
Alzheimers Res Ther. 2011 Apr 19;3(2):16
pubmed: 21504563
J Neuroinflammation. 2015 Aug 01;12:139
pubmed: 26232154
Int J Mol Sci. 2019 Jan 28;20(3):
pubmed: 30696107
Acta Neuropathol. 2013 Oct;126(4):479-97
pubmed: 24052108
Acta Neuropathol Commun. 2017 Sep 6;5(1):69
pubmed: 28877763
Neurology. 2010 Jan 12;74(2):106-12
pubmed: 20032288
Ageing Res Rev. 2013 Jan;12(1):289-309
pubmed: 22742992
Mol Neurobiol. 2019 Oct;56(10):7173-7187
pubmed: 30993533
PLoS One. 2013;8(2):e55091
pubmed: 23405115
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
Open Access J Clin Trials. 2020;12:1-13
pubmed: 32123490
Int J Mol Sci. 2021 Feb 15;22(4):
pubmed: 33672031
Clin Epigenetics. 2015 Oct 08;7:108
pubmed: 26457123
Science. 2012 Mar 23;335(6075):1503-6
pubmed: 22323736
Brain. 2016 Apr;139(Pt 4):1265-81
pubmed: 26921617
Ann Neurol. 2020 Jul;88(1):183-194
pubmed: 32468646
J Neurosci. 2002 Jan 1;22(1):10-20
pubmed: 11756483
J Clin Neurosci. 2019 Jan;59:6-11
pubmed: 30385170
BMC Neurol. 2016 Nov 22;16(1):236
pubmed: 27875990
Mol Neurodegener. 2018 Mar 1;13(1):11
pubmed: 29490706
PLoS One. 2009 Sep 30;4(9):e7258
pubmed: 19789626
Alzheimers Res Ther. 2016 Jan 29;8:4
pubmed: 26822146
Curr Alzheimer Res. 2017;14(4):403-411
pubmed: 28124585
Arch Pharm Res. 2015 Dec;38(12):2106-19
pubmed: 26289122
Nat Neurosci. 2019 May;22(5):719-728
pubmed: 30936558
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
BMJ. 2012 Mar 12;344:e1442
pubmed: 22411920
PLoS One. 2019 Oct 9;14(10):e0223578
pubmed: 31596896
Ann Neurol. 2015 Jul;78(1):88-103
pubmed: 25893674
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468